High Court Nixes Boehringer's Appeal In FTC Doc Row
The U.S. Supreme Court on Tuesday turned aside Boehringer Ingelheim Pharmaceuticals' appeal claiming that work product protections were cut in the company's fight with the Federal Trade Commission over access to...To view the full article, register now.
Already a subscriber? Click here to view full article